UK Shadow Health Minister Proposes Prescription-Only Vapes

Regulations by 2FIRSTS.ai
Dec.06.2023
UK Shadow Health Minister Proposes Prescription-Only Vapes
UK shadow health minister Wes Sterling suggests that e-cigarettes should be classified as prescription drugs to combat teen dependency.

According to a recent report from British daily newspaper The Telegraph, Wes Streeting, the Shadow Health Secretary, has suggested that the Labour Party is considering classifying e-cigarettes as prescription medications in order to curb the addiction of young people to this "gateway drug".

UK Shadow Health Minister Proposes Prescription-Only Vapes
Percentage of British teenagers who have previously tried e-cigarettes | Image source: The Telegraph

 

Sterling publicly accuses "Big Tobacco" and the e-cigarette industry of displaying a hypocritical attitude towards the issue of children inhaling smoke.

UK Shadow Health Minister Proposes Prescription-Only Vapes
2016: The population that frequently used e-cigarette products in 2016 | Image source: Daily The Telegraph 2021: The population that frequently used e-cigarette products in 2021 | Image source: Daily The Telegraph

 

During his visit to Australia last week, Sterling emphasized that the e-cigarette industry should "return to its origins" and only serve as a genuine smoking cessation aid, exclusively targeted towards those who are genuinely attempting to quit smoking.

 

Last week, the Australian government announced their plans to ban the import of disposable e-cigarettes in order to achieve their objective of making all e-cigarettes illegal without a prescription. Sterling, during an interview, revealed that he is considering implementing a similar policy after contacting the Australian Health Minister, Mark Butler.

 

Stirling states that the Labour Party is considering classifying e-cigarettes as prescription drugs in order to ensure that only adults attempting to quit smoking can access them, rather than them becoming a "gateway" for children to start smoking.

 

Sterling has not committed to any specific measures regarding e-cigarettes in the Labour Party's health plan. He emphasized the need to take an evidence-based approach to address this issue, as he does not want to throw out the baby with the bathwater.

 

I have consistently argued that e-cigarettes are better than smoking. Therefore, as a harm reduction service for transitioning from smoking to quitting, I believe e-cigarettes can be effective.

 

On Tuesday, Health Secretary Andrea Leadsom announced that the government will be proposing plans to restrict the sale of e-cigarettes to children at the earliest opportunity in the coming year. A public consultation on the matter will conclude on Wednesday.

 

We are aware that this industry targets children, which is unacceptable. Therefore, our Tobacco and e-cigarette Bill aims to restrict the appeal and availability of e-cigarettes among minors.

 

John Dunne, General Secretary of the UK e-cigarette Industry Association, has expressed concern over the idea of restricting e-cigarette access to prescriptions in Australia. He claims that this has created a significant black market, resulting in the widespread presence of unregulated and potentially unsafe e-cigarettes. As a result, the number of smokers in Australia is no longer declining as it is in other Western economies, with only 8% of e-cigarette users obtaining them through prescriptions.

 

The spokesperson for the Ministry of Health and Social Security stated:

 

We do not have plans to adopt the pure prescription e-cigarette model being implemented in Australia. Instead, we are consulting on a plan to reduce the availability, attractiveness, and affordability of e-cigarettes for children, while ensuring continued support for adults who want to quit smoking.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
From Border-Logistics Insiders to Retail Service Stations, Australia Mounts a Sweeping Crackdown on the Illicit Nicotine Trade as iGET Vapes Surface in A$80 Million Crime Networks
From Border-Logistics Insiders to Retail Service Stations, Australia Mounts a Sweeping Crackdown on the Illicit Nicotine Trade as iGET Vapes Surface in A$80 Million Crime Networks
Australian authorities have disclosed two major enforcement actions that go beyond product seizures and retail closures to examine how illicit tobacco and vape networks operate. On Aug. 14, the Multi Agency Strike Team said seven people had been charged and two criminal networks were valued by authorities at a combined A$80 million, or about US$56.8 million. Investigators allege the groups used bonded warehouses, freight businesses and “trusted insiders” in legitimate industries to circumvent border controls. In a separate operation on Aug. 11, more than 100 service stations were targeted as authorities sought information on illicit tobacco importation, distribution networks and the movement of sales proceeds.
Aug.17
China Discloses First Criminal Case Over Counterfeit Vapes Disguised as “Medical Nebulizers” and “Zero-Nicotine” Products
China Discloses First Criminal Case Over Counterfeit Vapes Disguised as “Medical Nebulizers” and “Zero-Nicotine” Products
Chinese authorities have disclosed the country’s first reported criminal case involving counterfeit vapes marketed as “medical nebulizers” and “zero-nicotine” products. Authorities determined that the products involved were counterfeit vapes and pursued criminal charges for producing and selling counterfeit goods. According to the report, the case resulted in the seizure of 347,000 counterfeit vape pods and 53,700 vape devices, with physical goods valued at 22.13 million yuan.
Aug.04
AIR Global Starts Debt Refinancing Four Months After Nasdaq Listing With About $400 Million Notes Expected
AIR Global Starts Debt Refinancing Four Months After Nasdaq Listing With About $400 Million Notes Expected
AIR Limited, a wholly owned subsidiary of AIR Global, has launched an offering of U.S. dollar-denominated senior unsecured notes, with proceeds primarily intended to repay its existing term loan and revolving credit facility. AIR has not disclosed the final size, maturity or coupon; Refinitiv, citing Moody's, reported an expected issuance of approximately $400 million and a Ba3 rating. AIR had about $412.4 million outstanding under the two bank facilities at June 30 and net debt of $344.8 million. In the first half of 2026, AIR's Al Fakher-led flavored shisha molasses business generated about 99% of company revenue, while New Growth Categories including Crown Switch produced $2.2 million in revenue and remained loss-making on an adjusted EBITDA basis.
Sep.23
China Tobacco Hubei explores staged nicotine pouch delivery, using dynamic membranes to slow early release and gradient particles to sustain later delivery
China Tobacco Hubei explores staged nicotine pouch delivery, using dynamic membranes to slow early release and gradient particles to sustain later delivery
China Tobacco Hubei Industrial Co., Ltd. disclosed several oral nicotine-related patent applications in August 2026, including two that approach staged nicotine release from different directions. One uses a high-viscosity membrane that forms inside the pouch after contact with saliva to slow rapid early release, while the other uses gradient particles with a faster-disintegrating outer layer and a slower core to create a fast-to-sustained release profile. Together, the filings explore how nicotine pouches could balance initial delivery with release later in use.
Sep.03
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23